Manufacturing & quality

Lilly lab employee looking at a colleague

Everyone deserves a chance at health

That’s why we’re working around the clock to bring life-changing medicines to people around the world. Whether it’s updates to existing sites or building new state-of-the-art facilities, continual investments in manufacturing expand our capacity to meet demand and deliver next-generation medicines.
Medicine vials on a conveyor line

Making medicines:
safety first, quality always

Have you ever wondered what it takes to make medicine? For most people, it’s not something you think about. That’s not the case for us. Manufacturing and Quality (M&Q) is a critical part of our mission and a responsibility we take seriously. Tens of thousands of employees work daily to ensure the quality and consistency of manufacturing of  our medicines.

But our manufacturing focus goes beyond the demands of today. We’re investing in the future. From the time a medicine shows promise in a clinical trial, we’re planning and preparing for the approval of the medicine, including investing in new facilities. We’ve launched 21 new medicines since 2014, with more expected in our pipeline. That’s why we’re constantly pursuing innovative ways to scale our global production and help more people—always with safety and quality standards front and center.

What does it take to make the medicines of tomorrow?

Our pipeline of future medicines—and their potential to help millions more patients—is driving the most significant manufacturing expansion in our history.
Tip jar icon

Investing in

significant manufacturing network expansion

bulleted-icon-list-item, icondescription-fs-24px
CPU icon

Using technology

to work faster while maintaining safety and quality

bulleted-icon-list-item, icondescription-fs-24px
Factory icon

Leveraging contract manufacturers

to enable more efficient delivery of medicines

bulleted-icon-list-item, icondescription-fs-24px

Huntsville, Alabama, USA

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px

We plan to invest more than $6 billion in a next-generation manufacturing site focused on small molecule synthetic and peptide medicines across various therapeutic areas.

Read more about the new Alabama site.

Katwijk, Netherlands

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px

This $3 billion investment will enhance our supply chain resilience and expand manufacturing capacity for our oral medicines across key therapeutic areas.

Read more details about the new Netherlands site.

Carolina, Puerto Rico, USA

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px

A $1.2 billion investment will expand and modernize our existing site, integrating advanced technologies and automation to support the reliable supply of high-quality oral medicines.

Read more about the expansion of the Puerto Rico site.

Houston, Texas, USA

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px

We plan to invest more than $6.5 billion in a new site that will focus on manufacturing small molecule synthetic medicines across our focus areas of cardiometabolic health, oncology, immunology and neuroscience.

Read more about the new Texas site.

Goochland County, Virginia, USA

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px
The first of four new sites to join our U.S. manufacturing network in 2025, the Goochland County, Virginia facility, will make cancer, autoimmune and other advanced therapies. The $5 billion site will be our first dedicated active pharmaceutical ingredient plant to support bioconjugate and large molecule medicines.

Read more details about the new Virginia site.

Kenosha County, Wisconsin, USA

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px

We announced a $3 billion expansion of the injectable manufacturing facility which we acquired in April 2024 in Kenosha County, Wisconsin, to support the increased demand for Lilly medicines. The acquisition, expansion and additional purchases of land and the adjacent warehouse bring our total planned investment in Wisconsin to $4 billion—the single largest U.S. manufacturing investment outside of our home state of Indiana. Medicine production at the existing state-of-the-art facility and the construction of the expansion are both planned to begin in 2025.

Read about the Kenosha County facility acquisition.

Read about the $3 billion expansion of the Kenosha County facility.

Limerick and Kinsale, Ireland

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px
The announcement of an additional $1 billion expansion of our Limerick manufacturing site brings the total investment to $2 billion. When complete, the facility will be a fully integrated site with advanced technologies including machine learning, AI and automated robotics systems designed to increase manufacturing speed and efficiency and support a reliable supply of safe Lilly medicines. The biologic active ingredients for our Alzheimer’s disease portfolio and future medicines will be produced at the Limerick facility.

Our Kinsale site employs a digital-first process that integrates continuous manufacturing technology to create a new manufacturing platform for complex peptides. An additional $800 million expansion to Kinsale’s pivotal site will help meet the demand and maintain a safe and reliable supply of Lilly’s diabetes and obesity medicines.

Read about the $1 billion expansion of the Limerick site.

Lebanon, Indiana, USA

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px

Our total investment in manufacturing facilities in Lebanon is $9 billion. This is the single largest investment in active pharmaceutical ingredient (API) manufacturing of synthetic medicines in U.S. history. In addition to delivering next-generation therapeutic modalities, including genetic medicines, we will boost production of API at this site.

Read about the $9 billion investment in the Lebanon, Indiana, manufacturing facility.

Research Triangle Park and Concord, North Carolina, USA

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px
We have invested nearly $3.7 billion in North Carolina, bringing state-of-the-art facilities and more than 1,000 new jobs to campuses in Research Triangle Park (RTP) and Concord. These facilities produce injectable medicines and delivery devices for Lilly medicines, helping to connect more people to the treatments they need for cancer, diabetes, cardiovascular, endocrine and neurodegenerative conditions.


Read about the Research Triangle Park expansion.

Read about the Concord investment.

Alzey, Germany

accordion-item, title-fs-24px, titlestyle-standardtitle, layout-1column, description-fs-16px

A $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, Germany. This new facility will further expand the company’s global injectable product and device manufacturing network and support increased demand for Lilly medicines, including its diabetes and obesity portfolio.

Read about the Alzey manufacturing site.

Innovation comes to life
in manufacturing

The push towards breakthrough discoveries isn’t confined to our labs. Innovation is embedded in all we do and helps us continue to find better, smarter, faster ways to reach more people.
Lilly scientist working in a lab

Manufacturing responsibly

Every detail related to our manufacturing efforts is a carefully calculated decision to ensure we’re responsible in our practices and thoughtful in our environmental and economic impact. With each new facility, we’re finding ways to support our larger sustainability goals by being closer to carbon neutral and using renewable energy.

What it takes to make a medicine

We often hear about the investment it takes to find the next great medicine. But ensuring those medicines can reach the people who need them also takes significant resources and can be just as complex. Our M&Q teams are constantly evolving and expanding capabilities to find the most cutting-edge ways to deliver. The teams are responsible for a diverse set of products and systems that help us create the active ingredients, the medicines themselves, and the devices to package and deliver those medicines. It's a complex, methodical, 
science-based process.

These sites require significant resources: specialized equipment, top-of-the-line facilities and highly skilled employees. We’re using robotics, automated guided vehicles, automated warehousing, and highly automated equipment to speed production. At one of our most recent sites using this technology in North Carolina, we are capable of doubling production compared to our other facilities. As we use more automation, we’re also investing in our team, providing extensive technical expertise and training for operators, technicians, engineers and scientists.

The flow of active ingredients to drug product to delivery devices to delivering medicines

The people behind the medicines

Thousands of employees are behind the scenes ensuring our medicines meet our quality and safety standards. A big part of making sure we have the right people on our team is making sure our employees are supported; empowered to learn and grow; and that we’re prioritizing their well-being and safety.

It takes diverse talent to make the medicines that so many around the world count on. From engineers who help continuously improve our facilities, equipment and processes, to technical services and operations team members who are front and center controlling production, every person in M&Q plays an important role in changing people’s lives.